XtalPi, a leader in AI and robotics for drug discovery, has announced a strategic collaboration with DoveTree LLC, founded by Harvard Professor Gregory Verdine, to develop therapeutics targeting oncology, autoimmune disorders, and neurological diseases.

The collaboration aims to create small molecule and antibody drug candidates specifically designed to address these critical health issues.

Professor Verdine emphasizes the transformative potential of integrating XtalPi's advanced AI capabilities with drug development expertise.

Verdine is a distinguished chemical biologist and entrepreneur, known for founding over ten biotechnology companies and significantly impacting drug development, particularly in oncology.

His notable contributions include the development of FDA-approved therapeutics such as romidepsin, paritaprevir, and glecaprevir, showcasing his influence in the biopharma sector.

In addition to his entrepreneurial ventures, Verdine has held advisory roles at major investment firms and research institutions.

As part of the collaboration, XtalPi will receive an upfront payment of $51 million, followed by an additional $49 million within 180 days, along with potential milestone payments exceeding $10 billion.

The agreement may also include tiered royalties on annual net product sales, further incentivizing the partnership.

DoveTree will hold exclusive global rights for the development and commercialization of the therapeutics resulting from this collaboration.

Founded in 2015 by MIT physicists, XtalPi utilizes quantum physics, AI, and robotics to provide innovative R&D solutions across various industries, including pharmaceuticals.

This strategic partnership underscores the growing intersection of technology and drug development, aiming to deliver groundbreaking therapies to market.